Ekso Bionics Holdings, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Note 14 - Stock-based Compensation (Tables)

Note 14 - Stock-based Compensation (Tables)

12 Months Ended

Dec. 31, 2023

Notes Tables

Share-Based Payment Arrangement, Activity [Table Text Block]

Original share pool			137
2015 increase			111
2017 increase			67
December 2017 increase (ratified in June 2018)			293
2019 increase			233
March 2020 increase			333
December 2020 increase			800
2022 increase			550
2023 increase			1,200
Total shares authorized for grant as of December 31, 2023			3,724

		*Shares Available*
		*For Grant*
Available as of December 31, 2022			50
Share pool increase			1,200
Granted			(1,023	)
Forfeited			32
Expired			18
Available as of December 31, 2023			277

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

										*Weighted*
						*Weighted*				*Average*
						*Average*				*Remaining*				*Aggregate*
		*Options*				*Exercise*				*Contractual*				*Intrinsic*
		*Outstanding*				*Price*				*Life (Years)*				*Value*
Outstanding at beginning of year			270			$	37.96
Forfeited			—			$	9.15
Expired			(18	)		$	63.02
Outstanding at end of year			252			$	36.17				3.49			$	—
Vested and expected to vest			252			$	36.17				3.49			$	—
Exercisable at year end			251			$	36.19				3.48			$	—

Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]

		Options Outstanding												Options Exercisable
						Weighted-Average
Range of						Remaining				Weighted								Weighted
Exercise		Number of				Contractual Life				Average				Number of				Average
Prices		Shares				(Years)				Price				Shares				Price
$5.55 - $5.70			71				6.06			$	5.68				70			$	5.68
$9.15 - $26.39			63				4.94			$	17.04				63			$	17.03
$26.85 - $54.15			74				4.50			$	31.45				74			$	31.46
$60.00 - $229.95			44				1.36			$	120.23				44			$	120.23
			252				4.50			$	36.17				251			$	36.19

Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]

						*Weighted*
		*Number of*				*Average Grant-*
		*Shares*				*Date Fair Value*
Unvested as of January 1, 2023			1,383			$	2.17
Granted			1,023			$	1.29
Vested			(1,069	)		$	1.96
Forfeited			(32	)		$	1.53
Unvested as of December 31, 2023			1,305			$	1.67

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

		*Years Ended December 31,*
		*2023*				*2022*
Sales and marketing		$	260			$	263
Research and development			423				339
General and administrative			1,175				1,944
		$	1,858			$	2,546